Physician profile
Patrick Tsui
NPI 1598949166
$7,495.03
in general payments reported to CMS, 2019-2025
27 companies · $564 in 2025
The $564 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,394 · 2020: $1,032 · 2021: $1,678 · 2022: $1,796 · 2023: $795 · 2024: $236 · 2025: $564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,595.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,595.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,724.78 | 2019-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $747.40 | 2019-2024 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals Lp | $715.25 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Biohaven Pharmaceutical Holding Company Ltd. | $628.74 | 2022 | |
| Pfizer INC. | $525.75 | 2019-2025 | |
| Abbvie INC. | $436.98 | 2020-2024 | Vraylar, Qulipta |
| Lilly USA, LLC | $408.03 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Biohaven Pharmaceuticals, INC. | $314.26 | 2020-2021 | |
| Esperion Therapeutics, INC. | $262.15 | 2020-2021 | |
| Kowa Pharmaceuticals America, INC. | $250.56 | 2019-2025 | Zoryve |
| Glaxosmithkline, LLC. | $227.68 | 2021-2023 | |
| Amarin Pharma, INC. | $168.11 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $162.33 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $131.31 | 2019-2022 | |
| Axsome Therapeutics, INC. | $123.07 | 2025 | Auvelity |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $106.46 | 2021-2023 | |
| Daiichi Sankyo INC. | $85.00 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.68 | 2019-2022 | |
| Genentech USA, INC. | $70.80 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $64.19 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.04 | 2021-2022 | |
| Allergan, INC. | $40.35 | 2020 | |
| Xeris Pharmaceuticals, INC. | $19.55 | 2023 | Gvoke Hypopen |
| Biocryst US Sales Co., LLC | $17.81 | 2021 | |
| Eisai INC. | $17.07 | 2021 | |
| Shire North American Group INC | $15.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Tsui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.